Enlivex Ltd.
No SEC Form 4 filings for $ENLV in the last 30 days.
The article previews a short U.S. and Canada market week after Memorial Day, highlighting housing, confidence, jobs, and earnings. It lists U.S. EPS results for PDD, AutoZone, Elbit, Salesforce, Synopsys, Marvell, Costco, Dell, and Autodesk, plus Canada banks’ and other firms’ EPS. Key data include S&P Case-Shiller (March), jobless claims and durable goods (May 23/April), and Canada payroll employment and GDP.
Enlivex Ltd. (NASDAQ: ENLV) has received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has an initial 180-day period, until November 9, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Failure to comply could lead to delisting, though Enlivex may be eligible for an additional 180-day period if other listing standards are met.
RedChip Companies will broadcast interviews with Enlivex Therapeutics (Nasdaq: ENLV) and Lantern Pharma (Nasdaq: LTRN) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV this Saturday, October 4th, at 7 p.m. ET. The interviews will cover Enlivex's positive Phase IIa results for Allocetra™ in knee osteoarthritis and Lantern Pharma's AI and machine learning platform, RADR®, for cancer drug discovery and development. Both companies will discuss their clinical pipelines and future development plans.
